Galapagos creates new warrant plan

On 20 January 2017, the Board of Directors of Galapagos approved the "Warrant Plan 2016 (B)," a warrant plan intended for an employee of a subsidiary of the Company, within the framework of the authorized capital. Under this warrant plan, 150,000 warrants were created (subject to acceptance) and offered to Dr. Walid Abi-Saab, who will start March 1 at Galapagos as Chief Medical Officer.

The warrants have an exercise term of eight years as of the date of the offer and have an exercise price of €62.50 (the closing price of Galapagos' shares on Euronext Amsterdam and Brussels on the last trading day preceding the date of the offer). The warrants are not transferable and can in principle not be exercised prior to the third anniversary of their issuance. Each warrant gives the right to subscribe to one new Galapagos share. Should the warrants be exercised, Galapagos will apply for the listing of the resulting new shares on a regulated stock market. The warrants as such will not be listed on any stock market.

Galapagos' total share capital currently amounts to €250,187,166.48; the total number of securities conferring voting rights is 46,256,078, which is also the total number of voting rights (the "denominator"), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights is 3,466,407, which equals the total number of voting rights that may result from the exercise of these warrants, and excludes the 150,000 warrants of Warrant Plan 2016 (B) which were created subject to acceptance. Galapagos does not have any convertible bonds or shares without voting rights outstanding.

About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our maturing pipeline comprises Phase 3, Phase 2, Phase 1, pre-clinical and discovery studies in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world. Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 480 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia.